TRAVERE THERAPEUTICS, INC. (TVTX)
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
📈 **POSITIVE** • High confidence analysis (95%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business